Valeant Pharmaceuticals International: firm’s  US shares rose about 8 per cent in premarket trading. Photograph: Christinne Muschi/Reuters

Valeant Pharmaceuticals International said its lenders had agreed to give it an extra month to file its annual report, providing further reassurance t(...)

Michael Pearson is to step down as  chairman of the board and chief executive officer of Valeant Pharmaceuticals International Inc.   The company has appointed activist investor William Ackman to its board. Photograph: Reuters

As recently as last summer, J Michael Pearson styled himself as a brash and bold executive with a new way of thriving in pharmaceuticals: buying othe(...)

Traders work on the floor of the New York Stock Exchange. Photograph: REUTERS/Lucas Jackson

Stocks propped up by buybacks binge The US bull market is looking dangerously dependent on corporate buybacks. Although the S&P 500 has soared, i(...)

The headquarters of Valeant Pharmaceuticals in Laval, Quebec. Photograph: Christinne Muschi/ Reuters

Embattled pharmaceutical company Valeant said its chief executive Michael Pearson will step down as it added Bill Ackman, one of its largest investors(...)

 Valeant Pharmaceuticals International  in Quebec: it has  incurred a heavy debt load because of a string of acquisitions. Photograph:  Christinne Muschi/Reuters

Valeant Pharmaceuticals International has cut its 2016 revenue forecast by about 12 percent and said a delay in filing its annual report could mean a (...)

Michael Pearson, chairman and chief executive officer of Valeant Pharmaceuticals: Deb Jorn’s departure  came after three tumultuous days following his  return   from a two-month medical leave. Photograph: Scott Eells/Bloomberg

Valeant Pharmaceuticals International, responding to investors’ queries, says executive vice-president Deb Jorn had not been asked to leave, reiterati(...)

Michael Pearson,  chief executive officer of Valeant Pharmaceuticals International. Photographer: Scott Eells/Bloomberg

Shares in embattled drugmaker Valeant Pharmaceuticals International fell up to 21 per cent as it said it was under investigation by the US Securities (...)

Michael Pearson, chairman and chief executive officer of Valeant Pharmaceuticals International, who has returned from a two-month absence due to illness. Photographer: Scott Eells/Bloomberg

Valeant Pharmaceuticals is withdrawing its financial forecast and will delay releasing fourth-quarter results, as chief executive Michael Pearsonretur(...)

A survey has found that just over half of investors expect Michael Pearson to return as Valeant chief executive after taking a leave of absence for medical reasons late last year.  Photograph: Bloomberg

Shares of Valeant Pharmaceuticals International Inc slumped about 18 per cent on Monday, the second consecutive day of steep declines, wiping out more(...)

The hedge fund of Bill Ackman has sold some of its shares in Valeant Pharmaceuticals, the embattled drug company that Mr Ackman earlier in 2015 went t(...)